Abstract
Arterial hypertension is a significant risk factor for the progression of chronic kidney disease (CKD) and is closely associated with cardiovascular events. This article reviews strategies for managing hypertension in CKD patients, emphasizing adequate blood pressure control, the use of antihypertensive medications and specific considerations for this population. A multidisciplinary, individualized approach, based on updated guidelines, is extremely important to minimize complications and improve clinical outcomes. Recent evidence suggests that a personalized approach is essential to balance blood pressure control and the preservation of renal function.
Keywords: Arterial hypertension; Chronic kidney disease; Clinical management; Antihypertensives; Cardiovascular complications
Introduction
Arterial hypertension is a prevalent condition and one of the main risk factors for cardiovascular and kidney diseases worldwide. It is estimated that more than 30% of the global adult population has hypertension and this prevalence increases substantially in individuals with chronic kidney disease (CKD)1. CKD, in turn, affects about 10% of the global population and is characterized by a progressive loss of renal function, often leading to the need for renal replacement therapy. The relationship between hypertension and CKD is bidirectional. Uncontrolled hypertension can accelerate the loss of renal function, while CKD contributes to resistance to antihypertensive treatment due to mechanisms such as activation of the renin-angiotensin-aldosterone system (RAAS), sodium and water retention and endothelial dysfunction2-4. Therefore, proper management of hypertension in CKD patients is crucial to slow disease progression, reduce cardiovascular risk and improve quality of life. Despite significant advances in hypertension management, several challenges persist in CKD patients5,6. These include the appropriate selection of medications, personalized blood pressure targets and the management of comorbidities. Recent guidelines highlight the importance of a patient-centered approach, using evidence-based strategies that consider the severity of CKD, associated clinical conditions and the risk of adverse events7.
Objectives
This article aims to review the current literature on hypertension management in CKD patients, addressing aspects such as blood pressure control targets, pharmacological and non-pharmacological therapies, as well as specific challenges faced by this population.
Materials and
Methods
Discussion
The approach to managing hypertension in CKD patients
involves a combination of pharmacological and non-pharmacological
interventions, as well as strict monitoring. Defining blood pressure targets is
key to preventing both the progression of CKD and cardiovascular complications.
Clinical guidelines generally suggest a target blood pressure lower than 130/80
mmHg, especially in patients with significant proteinuria8.
Drugs that inhibit the renin-angiotensin-aldosterone system
(RAAS), such as angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II receptor blockers (ARBs), are recommended as first-line therapy.
These medications not only lower blood pressure but also provide renal
protection by reducing proteinuria and slowing the progression of renal damage9. However, caution is
required in patients with hyperkalemia or severely compromised renal function.
Diuretics also play a critical role, particularly in the advanced stages of
CKD, where sodium and fluid retention are common. While thiazide diuretics are
effective in earlier stages, loop diuretics are preferred in more severe stages
due to their greater potency. In refractory cases, using mineralocorticoid
receptor antagonists, such as spironolactone, may be considered, although with
caution to avoid hyperkalemia10,11.
An important point to consider when using medications that
act on the RAAS and potassium-sparing diuretics is the propensity for
developing hyperkalemia. Patho physiologically, ACEIs, ARBs and
potassium-sparing diuretics (e.g., spironolactone and eplerenone) reduce the
production or action of aldosterone. Consequently, potassium excretion by the
distal tubules and collecting ducts of the nephron is diminished, leading to a
buildup of extracellular potassium. In CKD patients, the kidney’s potassium
excretion capacity is already compromised by the reduction in glomerular
filtration rate; therefore, the risk of hyperkalemia becomes even more
significant12. This condition can result in cardiac arrhythmias and, if
not properly monitored, may be fatal. For these reasons, frequent laboratory
monitoring of serum potassium levels is recommended for patients on these
classes of drugs, especially in advanced CKD stages and in individuals with
other associated comorbidities. Another relevant aspect in the management of dialysis-stage
patients is the indication of beta-blockers as a first-line antihypertensive
treatment. Recent studies suggest these drugs offer benefits in reducing
cardiovascular events, which are the main cause of morbidity and mortality in
this population. In hemodialysis patients, beta-blockers help control heart
rate, limit cardiac workload and may mitigate adverse effects related to
sympathetic overactivity13, common in advanced CKD. Furthermore, they appear to
reduce the incidence of fatal arrhythmias, which is particularly relevant in
individuals with frequent electrolyte imbalances. Thus, the use of
beta-blockers in dialysis patients is increasingly emphasized to improve
cardiovascular risk profiles and survival.
Non-pharmacological interventions, including reducing salt
intake, adopting healthy diets, weight control and regular physical exercise,
complement clinical management14,15. These strategies not only improve blood pressure control
but also metabolic and cardiovascular outcomes. Despite advances, gaps remain
in the management of hypertension in CKD. Treatment adherence continues to be a
challenge, particularly due to the complexities of therapeutic regimens and
medication side effects. In addition, the diversity of individual responses to
treatment highlights the need for a personalized approach, considering factors
such as age, comorbidities and treatment tolerance.
Conclusion
Managing hypertension in CKD patients requires a comprehensive approach that combines pharmacological and non-pharmacological interventions. Defining appropriate blood pressure goals and selecting medications carefully are essential to prevent the progression of renal disease and reduce cardiovascular risk. RAAS inhibitors, diuretics and mineralocorticoid receptor antagonists play central roles, while lifestyle modifications complement pharmacological therapy. Recent evidence reinforces the importance of an individualized approach, taking into account patients’ clinical characteristics and preferences. However, barriers such as poor treatment adherence and limited access to healthcare continue to negatively affect outcomes. Future research should explore new therapies and approaches to improve effectiveness and adherence, as well as identify biomarkers that help in risk stratification and personalized care. Promoting health education and providing multiprofessional support are critical to optimizing the management of hypertension in CKD patients, contributing to better clinical results and quality of life. Thus, integrated, patient-centered care must be the cornerstone of treatment for this vulnerable population.
References
1.
Agarwal R, Flynn J. Blood Pressure Control in Chronic Kidney Disease.
Clin J Am Soc Nephrol 2019.
2.
Bakris GL, et al. Optimizing Hypertension Management in CKD. Kidney Int
2020.
3.
Bilo G, et al. Home Blood Pressure Monitoring in CKD Patients. Nephrol
Dial Transplant 2020.
4.
Heerspink HJL, et al. Emerging Therapies for CKD. Nat Rev Nephrol 2021.
6.
KDOQI Clinical Practice Guidelines for Hypertension and CKD. Am J Kidney
Dis 2019.
7.
Levin A, et al. Global Burden of CKD. Lancet 2020.
8.
Patel RK, et al. Advances in Non-pharmacological Interventions for CKD.
J Am Soc Nephrol 2018.
9.
Pugh D, Gallacher PJ, Dhaun N. Challenges in
Hypertension Management in CKD. Clin Hypertens 2017.
10.
Rifkin De, et al. Sodium Intake and CKD Outcomes. Am J Kidney Dis 2019.
11.
Taler SJ, et al. Resistant Hypertension in CKD. Hypertension 2021.
12.
Townsend RR, et al. Renin-Angiotensin System Blockade in CKD. J Clin
Hypertens 2021.
13.
Webster AC, et al. Screening and Early Diagnosis of CKD. JAMA 2020.
14.
Whelton PK, et al. ACC/AHA Hypertension Guidelines 2017.